The introduction of NGS, with its rapid turnaround times and relatively low costs, has made more-thorough genomic screening possible, resulting in an even deeper understanding of the causes of complex diseases. As our knowledge has increased, so also has our appreciation for the potential of NGS for multi-biomarker testing in the clinical diagnostic context. However, there remain many obstacles to the widespread adoption of NGS in routine diagnostic testing, including the inherent complexity of the NGS workflow and the need to handle large amounts of sequencing data.